Clinical trial investigates osteoporosis medication for type 1 diabetes

Discovery enables better diagnosis and prognosis of the disease, possibly a cure.

Clinical trial investigates osteoporosis medication for type 1 diabetes

City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States and a top research center for diabetes and other life-threatening illnesses, is leading a phase 1/2 clinical trial investigating an osteoporosis medication as a way to improve beta cell health in people with early type 1 diabetes.

Osteoporosis cases are rising, but risk differs across demographics

While increased average life expectancy is a testament to modern medicine and public health efforts, an aging population comes with an increased presence of chronic diseases such as osteoporosis.

New Trial to Investigate Osteoporosis Drug for Type 1 Diabetes

The study explores whether Prolia/Xgeva (denosumab), a widely used therapy for osteoporosis and bone tumors, can regenerate beta cells in patients with early type 1 diabetes.

Osteoporosis risk assessment tools underperform in younger women

Three screening tools recommended by the U.S. Preventive Services Task Force (USPSTF) are suboptimal for identifying women who may be at risk for osteoporosis.

Dr. Lora Giangregorio Awarded Tier 1 Canada Research Chair in Bone Health and Exercise Science

Prime Highlights:  She also received a $75,000 grant from the Canada Foundation for Innovation John R. Evans Leaders Fund (JELF).  Dr. Giangregorio is renowned for her research on reducing osteoporotic fracture risk through exercise interventions.  Key Background:  Dr. Lora Giangregorio, Professor of Kinesiology and Health Sciences at the University of Waterloo, has been named a Tier 1 Canada Research Chair (CRC) in Bone Health and Exercise Scie…